65,437 trials
Renal Cell Carcinoma
Primary: AirSeal Reduction in the Variance of Intra-abdominal Pressure — 5.5; 1.3 mmHg
Pregnancy Related · Tobacco Use Disorder
Primary: Change in Cigarette Craving and Total Nicotine Withdrawal Symptoms Between Groups During Medication Treatment — 1.50; 2.07; 3.77; 5.35 MNWS Score
Carcinomas, Squamous Cell · Dysphagia
Primary: Outcome Compliance Rate — 76.2; 85.7 percentage of participants
Prostate Cancer
Primary: Efficacy of Satraplatin as Second Line Therapy in Men With CRCP — 4; 6; 3 participants
Melanoma
Primary: Phase I, Number of Participants With SAE and DLT — 0; 0; 1; 0 Participants
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 100.0; 100.0; 100.0 percentage of participants
Alcohol Dependence
Primary: Percent Change From Baseline in Heavy Drinking Days — -45.63; -39.72; -60.98; -49.88 percent of heavy drinking days
Recurrent Ptosis of the Breast
Primary: Nipple to Fold Measurement on Stretch — 2.3; 2.5; 1.4; 1.4 centimeters
Injections, Intravenous
Primary: Patient Expression of Pain — 0.76; 0.04 units on a scale
Breast Neoplasms
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0; 1 Participants
Pain
Primary: Between Group Difference in Change in Numerical Rating Scale (NRS) Pain Scores — 4.4; 3.5; 3.9; 4.3 units on a scale
Hypertension
Primary: Diastolic Blood Pressure Change — -8.56; -11.26 mmHg — p=0.0001
Pregnancy
Primary: Number of Participants With Accurate Epidural Placement — 21; 23 Participants
Hepatitis B
Primary: Percentage of Subjects With Seroprotective Immune Response — 95.1; 81.3 Percentage of Participants
Obstructive Coronary Artery Disease · Coronary Artery Disease
Primary: Correlation Between Plaque Morphology and HDL Functionality — 0.30 beta coefficient